SPossibilities of 4-Component Therapy in Renal Protection: UNIKUM Trial Results

Authors

  • D.D. Ivanov Chief of Chair of Nephrology And Renal Replacement Therapy Of National Medical Academy Of Postgraduate education named after P.L. Shupik, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.0.1.2012.176444

Keywords:

4-component therapy, UNIKUM, fixed combination, polypill, efficiency of combined therapy

Abstract

There are given the results of first in Ukraine experience of 4-component therapy (angiotensin II receptor blockers, β-blocker, acetylsalicylic acid, statin) — multimodal strategy under randomized study in patients with chronic renal disease. Convincing data on decrease of blood pressure, microalbuminuria and improvement of lipid profile at positive dynamics of glomerular filtrate rate are obtained. In comparison with efficacy of fixed combination (polypill) there was assessed advisability of this regimen in patients with chronic renal disease, asl well as marketing opportunity of generic polypill creation in Ukraine.

Downloads

Download data is not yet available.

References

PILL Collaborative Group. An international randomized placebo-controlled trial of four-component combination pill («poly­pill») in people with raised cardiovascular risk // PloSOne 2011. — DOI:10.1371/jornal.pone0019857.

Gaziano T.A., Opie L.H., Weinstein M.C. Cardiovascular di­sease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis // Lancet. — 2006. — 368. — 679-685.

Hueiming L., Patel А., Brown А. et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomized controlled trial of a polypill-based strategy amongst Indigenous and non indigenous people at high cardiovascular risk // BMC Public Health. — 2010. — 10. — 458.

Ruggenenti P. et al. Role of remission clinics in the longitudinal treatment of CKD // J. Am. Soc. Nephrol. — 2008. —19. —1213-1224.

The Remission Clinic approach to halt the progression of kidney disease / The Remission Clinic Task Force Clinical Research Center «Aldo e Cele Dacc?» // J. Nephrol. — 2011. — 24(03). — 274-281.

http://www.surveysystem.com/sscalc.htm.

Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. — 2011. — 32(14). — 1769-1818.

Yusuf S. Two decades of progress in preventing vascular disease //Lancet. — July 2002. — 360 (9326). — 2-3. DOI:10.1016/S0140-6736(02)09358-3. PMID 12114031.

Yusuf S., Pais P., Afzal R. et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial // Lancet. — 2009. — 373 (9672). — 1341-51. DOI:10.1016/S0140-6736(09)60611-5. PMID 19339045.

The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial // Lancet. — 2009. — 373. — 1341-1351.

Www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61584-1/fulltext

Www.sph.uq.edu.au/docs/BODCE/ACE-P/ACE-P_pamphlet_3.pdf

Downloads

Published

2022-02-15

How to Cite

Ivanov, D. (2022). SPossibilities of 4-Component Therapy in Renal Protection: UNIKUM Trial Results. KIDNEYS, (1), 33–36. https://doi.org/10.22141/2307-1257.0.1.2012.176444

Issue

No. 1 (2012)

Section

Original Articles

License

Copyright (c) 2012 D.D. Ivanov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.